File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients

TitleA double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients
Authors
Issue Date2001
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/4294
Citation
International Journal Of Geriatric Psychiatry, 2001, v. 16 n. 12, p. 1156-1162 How to Cite?
AbstractBackground: Behavioural and psychological (BPSD) are common during the course of dementia and present severe problems to patients and their caregivers. Objectives: To assess the therapeutic efficacy and safety of haloperidol and risperidone in treating BPSD in Chinese dementia patients. Methods: A 12-week double-blind randomised comparison of haloperidol and risperidone treatments was conducted in 58 patients with DSM-IV diagnosis of dementia of Alzheimer's type or vascular dementia. They were randomly assigned to receive flexible doses (0.5 to 2 mg/day) of haloperidol or risperidone. Clinical response was evaluated using the Cohen-Mansfield Agitation Inventory (CMAI), the Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), Simpson-Angus Scale, Functional Assessment Staging and Cantonese version of the Mini-Mental State Examination. Results: The mean doses at the last week were 0.90 mg/day of haloperidol and 0.85 mg/day of risperidone. Both haloperidol and risperidone significantly reduced the severity of BPSD (scores on CMAI an BEHAVE-AD), with no significant between-group differences. Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperodine-treated patients. Conclusions: Low-dose haloperidol and risperidone were well tolerated and associated with reductions in the severity and frequency of behavioural symptoms in subjects with dementia. Risperidone may have a more favourable risk-benefit profile in view of its lower propensity to induce extrapyramidal symptoms. Copyright © 2001 John Wiley & Sons, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/174234
ISSN
2015 Impact Factor: 2.699
2015 SCImago Journal Rankings: 1.382
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, WCen_US
dc.contributor.authorLam, LCWen_US
dc.contributor.authorChoy, CNPen_US
dc.contributor.authorLeung, VPYen_US
dc.contributor.authorLi, SWen_US
dc.contributor.authorChiu, HFKen_US
dc.date.accessioned2012-11-22T02:01:25Z-
dc.date.available2012-11-22T02:01:25Z-
dc.date.issued2001en_US
dc.identifier.citationInternational Journal Of Geriatric Psychiatry, 2001, v. 16 n. 12, p. 1156-1162en_US
dc.identifier.issn0885-6230en_US
dc.identifier.urihttp://hdl.handle.net/10722/174234-
dc.description.abstractBackground: Behavioural and psychological (BPSD) are common during the course of dementia and present severe problems to patients and their caregivers. Objectives: To assess the therapeutic efficacy and safety of haloperidol and risperidone in treating BPSD in Chinese dementia patients. Methods: A 12-week double-blind randomised comparison of haloperidol and risperidone treatments was conducted in 58 patients with DSM-IV diagnosis of dementia of Alzheimer's type or vascular dementia. They were randomly assigned to receive flexible doses (0.5 to 2 mg/day) of haloperidol or risperidone. Clinical response was evaluated using the Cohen-Mansfield Agitation Inventory (CMAI), the Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), Simpson-Angus Scale, Functional Assessment Staging and Cantonese version of the Mini-Mental State Examination. Results: The mean doses at the last week were 0.90 mg/day of haloperidol and 0.85 mg/day of risperidone. Both haloperidol and risperidone significantly reduced the severity of BPSD (scores on CMAI an BEHAVE-AD), with no significant between-group differences. Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperodine-treated patients. Conclusions: Low-dose haloperidol and risperidone were well tolerated and associated with reductions in the severity and frequency of behavioural symptoms in subjects with dementia. Risperidone may have a more favourable risk-benefit profile in view of its lower propensity to induce extrapyramidal symptoms. Copyright © 2001 John Wiley & Sons, Ltd.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/4294en_US
dc.relation.ispartofInternational Journal of Geriatric Psychiatryen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAlzheimer Disease - Diagnosis - Drug Therapy - Psychologyen_US
dc.subject.meshDementia, Vascular - Diagnosis - Drug Therapy - Psychologyen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHaloperidol - Adverse Effects - Therapeutic Useen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshRisperidone - Adverse Effects - Therapeutic Useen_US
dc.subject.meshSocial Behavior Disorders - Diagnosis - Drug Therapy - Psychologyen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleA double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patientsen_US
dc.typeArticleen_US
dc.identifier.emailChan, WC: waicchan@hku.hken_US
dc.identifier.authorityChan, WC=rp01687en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/gps.504en_US
dc.identifier.pmid11748775-
dc.identifier.scopuseid_2-s2.0-0035674311en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035674311&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue12en_US
dc.identifier.spage1156en_US
dc.identifier.epage1162en_US
dc.identifier.isiWOS:000173068000006-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridChan, WC=16400525900en_US
dc.identifier.scopusauthoridLam, LCW=7201984627en_US
dc.identifier.scopusauthoridChoy, CNP=18934166900en_US
dc.identifier.scopusauthoridLeung, VPY=7102336030en_US
dc.identifier.scopusauthoridLi, SW=7409240495en_US
dc.identifier.scopusauthoridChiu, HFK=7401986628en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats